Larvol Delta - Inhibikase-Therapeutics-Announces-First-Patients-Dosed-in-Phase-1-Clinical-Trial-of-IkT148009-to-Treat-Parkinsons-Disease-and-Related-Disorders

IkT-148009 - Inhibikase, Clintrex

https://www.businesswire.com/news/home/20210217005288/en/Inhibikase-Therapeutics-Announces-First-Patients-Dosed-in-Phase-1-Clinical-Trial-of-IkT-148009-to-Treat-Parkinson%E2%80%99s-Disease-and-Related-Disorders

Feb 17, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next